EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSAPOG00000005286
Gene Symbol: GABRG2
3 Cross references
213 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSAPOG00000002403
Gene Symbol: GABRG3
4 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSAPOG00000001215
Gene Symbol: GABRG3
2 Cross references
222 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAPOG00000008685
Gene Symbol: GABBR1
3 Cross references
199 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSAPOG00000019594
Gene Symbol: GABBR1
3 Cross references
191 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSAPOG00000001649
Gene Symbol: GABBR2
3 Cross references
207 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSAPOG00000009227
Gene Symbol: LOC110951636
3 Cross references
193 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSAPOG00000009850
Gene Symbol: GLP2R
2 Cross references
204 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSAPOG00000014092
Gene Symbol: GCGR
3 Cross references
163 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSAPOG00000012757
Gene Symbol: LOC110966907
3 Cross references
207 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSAPOG00000016514
Gene Symbol: LOC110966808
2 Cross references
206 Possible Orthologues:

Glucokinase

Ensembl ID : ENSAPOG00000006075
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).